Oxygen Targets in Acute Heart Failure With Pulmonary Congestion
Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Nov 4, 2022
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best way to provide oxygen to patients who are hospitalized with acute heart failure and experiencing difficulty breathing due to fluid buildup in the lungs (known as pulmonary congestion). The trial will compare two different oxygen strategies: one group will receive enough oxygen to keep their levels at 96%, while the other group will aim for a lower target of 90%. This research aims to find out which oxygen target is more effective for helping patients in this situation.
To be eligible for the trial, participants must be at least 18 years old and have recently experienced worsening shortness of breath, along with a low oxygen level (below 92%). They should also show signs of fluid in the lungs through clinical exams or imaging tests. Participants will be randomly assigned to one of the two oxygen groups using a special machine that delivers oxygen, ensuring that neither the patients nor the healthcare team knows which group they are in. The study will include 122 patients, and those who qualify can expect close monitoring and care during their hospital stay. It's important to know that this trial is currently recruiting patients and aims to help improve treatment strategies for acute heart failure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years
- • 2. Acute (within minutes to days) onset or worsening of subjective dyspnea
- • 3. Oxygen saturation \<92% (on arterial blood gas) or need of oxygen
- 4. At least one of the following clinical or radiological signs of congestion:
- • 1. Pulmonary rales 2. Chest X-ray or CT with pulmonary congestion 3. Lung ultrasound with multiple B-lines
- Exclusion Criteria:
- • 1. More than 4 hours from hospital admission to randomization
- • 2. Suspected infection or sepsis
- • 3. Known severe pulmonary disease
- • 4. Systolic blood pressure \<90 mmHg
About Copenhagen University Hospital, Hvidovre
Copenhagen University Hospital, Hvidovre, is a leading clinical research institution in Denmark, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent academic hospital affiliated with the University of Copenhagen, it integrates cutting-edge research with clinical practice, fostering innovation in various medical fields. The hospital is dedicated to conducting rigorous clinical trials, ensuring adherence to ethical standards and regulatory guidelines, while prioritizing patient safety and welfare. With a multidisciplinary approach and access to diverse patient populations, Copenhagen University Hospital, Hvidovre plays a vital role in translating research findings into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, Capital Region, Denmark
Copenhagen, , Denmark
Patients applied
Trial Officials
Jens Hove, MD, PhD
Study Chair
Copenhagen University Hospital Amager-Hvidovre Department of Cardiology
Johannes Grand, MD, PhD
Principal Investigator
Copenhagen University Hospital Amager-Hvidovre Department of Cardiology
Ida Taraldsen, MD
Study Director
Copenhagen University Hospital Amager-Hvidovre Department of Cardiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials